Pfizer was Palvella Therapeutics’s largest revenue line in fiscal 2023, bringing in $15.13M of $42.81M (35%).
| Counterparty Name | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Astra Zeneca A B | — | $18.92M | $9.12M | $8.40M | |||||
| Astrazeneca | $8.31M | — | — | — | |||||
| Pfizer | — | — | $8.29M | $15.13M | |||||
| Les Laboratoires Servier & Institut De Recherches Internationales Servier | — | $4.07M | $5.36M | $4.10M | |||||
| Servier | $11.31M | — | — | — | |||||
| Genentech | — | $1.95M | $3.14M | $12.70M | |||||
| Seagen | $9.70M | — | — | — | |||||
| Seattle Genetics | — | — | — | — | |||||
| Boston Pharmaceuticals | — | $5.71M | — | $2.48M | |||||
| Roche | — | — | — | — | |||||
| Other | — | — | — | — | |||||
| Collaboration Partner One | — | — | — | — | |||||
| Seattle Genetics Inc | — | $768.00K | — | — | |||||
| Collaboration Partner Two | — | — | — | — | |||||
| Government Grant | — | — | — | — | |||||
| Total | $29.32M | $31.42M | $25.90M | $42.81M |
Palvella Therapeutics brought in $42.81M from its five revenue lines in fiscal 2023, the year ended December 31, 2023. Palvella Therapeutics regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $25.90M. Pfizer was the largest at $15.13M (35.4%), ahead of Genentech at $12.70M (29.7%) and Astra Zeneca A B at $8.40M (19.6%). The other two revenue lines brought in $6.58M combined.
Compared with fiscal 2022, Genentech grew fastest, up 304.5% to $12.70M, while Les Laboratoires Servier & Institut De Recherches Internationales Servier fell the most, down 23.5% to $4.10M.
Palvella Therapeutics began breaking out Astra Zeneca A B in fiscal 2021, Pfizer in fiscal 2022, Les Laboratoires Servier & Institut De Recherches Internationales Servier in fiscal 2021 and Genentech in fiscal 2021. Palvella Therapeutics stopped reporting Servier ($11.31M in fiscal 2020), Seagen ($9.70M in fiscal 2020), Astrazeneca ($8.31M in fiscal 2020) and one other as separate revenue lines.
Customer Revenue was Palvella Therapeutics’s largest product and service line in fiscal 2019, bringing in $32.07M of $46.28M (69%).
| Product and Service | FY 2019 |
|---|---|
| Customer Revenue | $32.07M |
| Collaboration Revenue | $14.21M |
| Total | $46.28M |
Palvella Therapeutics brought in $46.28M from its two product and service lines in fiscal 2019, the year ended December 31, 2019. Customer Revenue was the largest at $32.07M (69.3%), ahead of Collaboration Revenue at $14.21M (30.7%).
Palvella Therapeutics (PVLA) reports its revenue by counterparty name and by product and service. In fiscal 2023, Pfizer was its largest revenue line, bringing in $15.13M (35.4% of the total), followed by Genentech at $12.70M (29.7%).
Pfizer was Palvella Therapeutics' largest revenue line in fiscal 2023, bringing in $15.13M, or 35.4% of the $42.81M total across its five revenue lines.
Customer Revenue was Palvella Therapeutics' largest product and service line in fiscal 2019, bringing in $32.07M, or 69.3% of the $46.28M total across its two product and service lines.
Every figure comes from Palvella Therapeutics' annual financial filings, as reported. Each line keeps the name Palvella Therapeutics gives it, and years follow its fiscal calendar.
Palvella Therapeutics' revenue by counterparty name goes back to fiscal 2015, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.